Vol. 19/No. 17 | OncologyLive

Frontline Quizartinib Is Tested in AML Subgroup

September 06, 2018

Quizartinib, a small molecule receptor tyrosine kinase inhibitor targeting FLT3, is currently being evaluated in combination with chemotherapy in patients with newly diagnosed FLT3-ITD–positive AML.

A Legacy of Hope for Young Leukemia Patients

September 03, 2018

Joseph V. Simone, MD, is best known for leading the research efforts that resulted in the first curative combination treatment for certain pediatric patients with acute lymphoid leukemia. Under his leadership, the St. Jude Children’s Research Hospital in Memphis, Tennessee, was designated the first and only National Cancer Institute cancer center dedicated to children. He was honored in the Pediatric Oncology category with a 2017 Giants of Cancer Care® award.

ASCO Endorses Complementary Therapy Guidelines for Patients With Breast Cancer

August 31, 2018

In an effort to address strategies that many patients with cancer are adopting, ASCO has endorsed recommendations regarding the use of complementary therapies to manage symptoms and adverse effects of breast cancer treatment.

Testing for RET Alterations Gains Traction Across Tumor Types

August 30, 2018

In recent years, tyrosine kinase inhibitors that specifically target RET have entered the pipeline. Although none have yet received FDA approval, the promise of these agents has spurred interest in diagnostic assays.

Looking Beyond Overall Survival in Chronic Myeloid Leukemia

August 30, 2018

As investigators continue to look for ways to improve outcomes for the growing number of patients with CML, the primary goal has shifted from improving overall survival to helping patients achieve treatment-free remission.